Glomus Jugulare Tumours
In 1945, I reported a case which was characterized as a tumour, like the carotid body tumour, involving the middle ear, mastoid and temporal bone (Rosenwasser 1945) . The tissue removed was identical with a proven carotid body tumour from its typical site in the neck. From Guild's report (1941) , it could be inferred that the tumour removed might have developed from this glomus structure.
Dr Sadao Otani, the pathologist, originally reported (Rosenwasser 1945 ) that the tissue removed was a fragment measuring 9 by 7 mm, covered with a squamous cell layer immediately beneath which was an unusual tumour structure. Large tumour cells in groups were separated by dense fibrous tissue septa containing dilated vessels. The group of tumour cells was bordered by capillaries and formed small alveolar structures. The alveolar arrangement of the tumour cells was not always distinct and showed compressed cord-like structures in places. The wellpreserved tumour cells were large and polyhedral and their nuclei rather small and not hyperchromatic. The large cytoplasm was frequently vacuolated which obscured cell outlines. The oval nuclei were uniform, although there were areas in which the tumour cell nuclei varied in shape. There were no mitotic figures.
In the past 28 years I have reported metastases from glomus jugulare tumours (Rosenwasser 1958) and discussed the nomenclature and management of these tumours (Rosenwasser 1952 (Rosenwasser , 1967 (Rosenwasser , 1968 (Rosenwasser , 1969 (Rosenwasser , 1973 . Some points concerning the differential diagnosis and management of glomus tumours will here be discussed.
General Considerations
Nomenclature: In the original report (Rosenwasser 1945) this growth was described as a carotid body-like tumour because it resembled known carotid body tumours in the neck. Since then, many names have been suggested: glomus jugulare tumour (Winship 1948) , non-chromaffin paraganglioma (Lattes & Waltner 1949) , chemodectoma (Mulligan 1950) , receptoma (Gaffney 1953) , glomerocytoma (Zettergren & Lindstrom 1951) , tympanic body tumour (Lundgren 1949) , and chemoreceptoma (Mulligan 1950) .
The function of the carotid body in the neck is chemoreceptive, but there are no indications that the glomus jugulare has this, or indeed any other function. According to Boyd et al. (1959) , 'with our present lack of knowledge of their physiology, the inclusion of chemodectomas (glomus jugulare tumours) as chemoreceptors, as has been done by a number of investigators, seems to us to be presuming an analogy in function between these structures and the carotid body, when the homology between them is still in doubt'. It is apparent that further work must be done to establish the function of the glomus jugulare structure on the inner tympanic wall, middle ear and jugular bulb area. It is expected that more electron microscopy studies of the cells of this tumour will shed light on the function of the glomus jugulare.
Distribution: Glomus jugulare bodies have been found in the so-called normal location, adjacent to the dome of the jugular bulb and along the course of that branch of the glossopharyngeal nerve as it extends through the bony floor of the middle ear. These 'normal' structures have been noted on the inner tympanic wall, along the course of the facial nerve, in the nose and nasopharynx and intracranially. They may also be found aberrantly in the trachea, temporal bone and optic chiasm. Wherever these structures are, there I 259 exists the possibility that a tumour may develop from them and present the unquestioned histology of a glomus jugulare tumour. I have seen such a tumour in an excised brain cyst wall and also as an isolated encapsulated lesion in the trachea. The mechanism which triggers these aberrantly placed structures, as well as the normally located structures, to develop into growing, mature tumours is unknown.
Norepinephrine-secreting properties: It is necessary to draw attention to -the rare instances when patients with glomus jugulare tumours have signs and symptoms of a phiochromocytoma. Whenever a patient with such a tumour has severe primary hypertension, a careful investigation using specific tests to rule out a possible phaeochromocytoma must be made before surgery is contemplated. DeLellis & Roth (1971) reported a case in which a functioning glomus jugulare tumour contained 9.4 mg norepinephrine per gram tissue. Despite this high concentration of catecholamine, the chromaffin reaction was negative.
Cases of this kind should be carefully investigated and reported. Alarming falls in blood pressure during the course of surgery are not, in my opinion, always related to sudden severe blood loss, and the possibility that they are related to certain lesser known characteristics of these tumours should be considered.
Multicentricity: Bickerstaff & Howell (1963) have stated that 10% glomus jugulare tumours are multicentric. I recall a case in which a small, circumscribed lesion in the middle ear was removed. Histologically the tumour appeared quite benign, with relatively few cellular elements, and fewer and smaller vascular spaces. In less than two years this patient developed a large bone defect which involved so much of the petrous pyramid, sublabyrinthine area and jaw joint that, at a second hospital, it was considered inoperable. This patient then entered a third hospital where the area was explored. The surgeon sent me slides of tissue removed from the apparent recurrence in the middle ear, and from the under-surface of the petrous pyramid. Comparison with the original tissue removed revealed a different histological appearance. This case suggests that by removing the relatively benign glomus jugulare tumour, there resulted a malignant activation of a small, clinically quiescent multicentric focus, separate from the original focus but close enough to give the impression of a recurrence. Pathologists know that some multicentric tumours in other areas frequently do this. I do not feel this was a recurrence, but rather the development of a separate tumour with strikingly different histological and clinical characteristics. This cannot be proved, but is the only way the different properties of this glomus jugulare tumour can be reconciled. This patient was explored recently for a carotid body tumour in the neck on the opposite side and a third glomus tumour was removed. The patient is doing well and is being followed up by Dr John Daly.
Diagnosis
The diagnosis of glomus jugulare tumour confined to the middle ear may appear relatively simple. My experience does not entirely support this belief. There are many cases in which the lesion is small, circumscribed and confined to the middle ear. The eardrum may appear purplish red and there may be a mild conductive hearing loss, with tinnitus. X-rays reveal a small lesion in the middle ear cavity. These cases cause little or no difficulty in diagnosis. There are, however, other cases in which the tumour arises in the region of the jugular bulb and grows asymptomatically. Only at a relatively late stage does it erode the floor of the hypotympanum, presenting as a seemingly small lesion in the middle ear. I saw a patient who had had three operations, each for local removal of a supposedly small recurrent glomus jugulare tumour. She had a fourth operation, a radical mastoidectomy, because the recurrent tumour now filled the middle ear, aditus and antrum. I witnessed this last procedure and it seemed that this tumour was totally removed. About six months later, the patient was sent to me by the otologist who was quite proud of the beautifully epithelialized cavity. The cavity was beautiful, but I noted a slight deviation of the tongue, a partial recurrent paralysis and some shoulder girdle muscle weakness beginning. Subsequent investigations revealed a large lesion involving the jugular foramen and undersurface of the temporal bone. This course is not unusual, and points out the necessity of adequate investigation. Small lesions in the middle ear may merely be the top of a large destructive lesion below. Clinically, glomus jugulare tumours may simulate a refractory otitis media. Too often patients are treated for refractory otitis media for as long as a year with every known type of antibiotic, antihistamine, cortisone, &c., before diagnosis of glomus jugulare tumour is made.
Clinically, one may encounter cases in which the patient presents with a bluish ear drum, conductive hearing loss and spontaneous bleeding from the middle ear, extensive destruction in the mastoid bone and the bony posterior canal wall, with a large exposure of facial nerve but no glomus jugulare tumour to be found. The destruction was caused by infection; the symptoms of which were masked by the persistent intermittent use of antibiotics. Not all patients with spontaneous bleeding, buzzing and bluish appearing drum have a glomus jugulare tumour.
Too often patients are explored because of a dusky mass in the middle ear cavity, a mild conductive hearing loss and tinnitus, and are suspected ofhaving a glomus jugulare tumour. I know of 5 instances in which, instead of tumour, the surgeon encountered a prominent, dehiscent, high jugular bulb, the results of which can be serious.
Clinically, cases may present with jugular foramen syndromes, arterial bruit, dead labyrinths or facial paralysis, which simulate angle tumours. The symptoms depend on how long these patients have had their lesions before they seek help. Clinically, glomus jugulare tumours may present with signs and symptoms of brain tumour and are referred by the neurologist or neurosurgeon, especially if there is a discernible lesion in the middle ear or external auditory canal. To emphasize further some of the difficulties in diagnosis, I have listed in the following table 6 cases in which the tentative preoperative diagnosis was glomus jugulare tumour. All of these cases were referred to me for surgery. In each instance the procedure was an exploratory one, which I felt necessary even though I was unsure of the underlying pathology. Haemotympanum, secondary to extensive mastoid bone destruction, and cholesteatoma with bleeding and meningioma were found rather than a glomus jugulare tumour. There are rare instances in which transtympanic exploration for suspected glomus jugulare tumour revealed fibrous dysplasia, adenoma and melanoma.
In the differential diagnosis, the complaint of pain is important. It is a very uncommon symptom in patients with glomus jugulare tumours. Patients with large lesions involving the middle ear, mastoid and undersurface of the temporal bone who did not complain of pain must have been seen. In my experience patients do not have pain unless there is concomitant infection of the mastoid bone. At the Armed Forces Institute of Pathology in Washington, DC there are 88 cases of glomus jugulare tumours on record and only 2 had pain. I know of 2 cases diagnosed as glomus jugulare tumour with severe pain as an outstanding complaint: one proved to have metastatic adenocarcinoma from a primary lesion in the prostate, the other had undifferentiated carcinoma arising in the nasopharynx with a benign glomus jugulare tumour in the middle ear. In the absence of middle ear infection or of an external otitis, a patient complaining of pain, with a lesion confined to the middle ear, mastoid and temporal bone, is more likely to have another type of malignancy rather than a glomusjugulare tumour. Treatment by Surgery Any rational surgical treatment must depend on an assessment of the extent of underlying pathology. Patients have been divided into three groups. Group 1 includes cases in which the lesion is small, circumscribed and confined to the middle ear cavity; the ossicular chain is uncompromised and there is a conductive hearing loss. Group 2 includes cases where the middle ear, aditus, antrum and mastoid are involved by tumour; the degree of involvement, even after careful investigation, can only be established accurately by exploratory surgery. In Group 3 are included all cases in which there is widespread extension along the undersurface ofthe temporal bone, often into the pyramid and sometimes into the cranial cavity.
Group 1: A transtympanic approach is adequate for comiiplete removal in almost all cases merely by elevating a flap sufficient for the necessary exposure. When the lesion extends superiorly behind the manubrium of the malleus, additional exposure can be obtained by dissecting the attachment of the drum from the malleus and then reflecting the flap upward. If the tumour can be removed in toto bleeding is usually not a problem.
I have noted that when removal of the tumour is total the pre-existing tinnitus disappears. The return of tinnitus after it has disappeared usually means recurrence of growth. Failure of tinnitus to disappear has been interpreted by me as failure to accomplish total removal or the possible presence of an unrecognized adjacent multicentric focus.
Group 2: If, on the basis of careful clinical evaluation plus tomography and arteriography, it is found that the lesion spreads beyond the middle ear cavity, involving the aditus, antrum and mastoid, an exploratory mastoid operation is always performed. If assessment of the extent of the lesion is confirmed, a well-performed radical mastoidectomy is adequate to encompass the disease. If the proper wide exposure of the lesion is obtained early without causing bleeding from the tumour, the likelihood of total removal is improved, If it becomes apparent that there is tumour in the neck or undersurface of the temporal bone and about the jugular foramen, it is obvious that radical mastoidectomy alone will not suffice. In those instances radical mastoidectomy must be combined with exploration of the upper neck to provide access to the jugular bulb area. Adequate exposure is the key to successful removal.
Group 3: Included here are those cases in which the tumour is so far advanced that the only hope for surgical cure lies in the total removal of the temporal bone. This has been done successfully and is recommended by others, but I am not one of its enthusiastic proponents. In these cases I recommend irradiation.
Treatment by Irradiation
The best results are obtained by irradiation if the extent of the tumour can be accurately defined. This enables the radiotherapist to substantially reduce the volume of normal tissue exposed to irradiation, confining the irradiation to the involved area. Radiotherapists are aware that previous surgery enhances the risk of osteoradionecrosis, especially if there is exposed bone or persistent infection. There are widely disparate views as to the amount of irradiation necessary to cure these tumours in situ. Our radiotherapist treats these patients with full normal tissue tolerance dosage, 4500-5500 rad delivered over 4-6 weeks, and usually employing cobalt-60 teletherapy because radiation reactions are fewer with this. We have had good results in the early days with 200 kV type irradiation and more recently with high voltage therapy.
In view of the unpredictable growth rate of glomus jugulare tumours one can hardly be dogmatic in regard to irradiation or the results of any method of treatment. Patients with large tumours have been known to live untreated for 3040 years. Therefore, when one speaks of patients with this lesion treated with irradiation, one should more properly speak of years of survival rather than radiocurability. From the literature, it appears that glomus jugulare tumours have been regarded as radioresistant by some and responsive to irradiation by others. I believe these widely disparate views can be reconciled by stating that these tumours may require more irradiation than other radiosensitive tumours in the same location. Some have expressed doubt that irradiation alone has ever cured a patient with this lesion. It has been asserted that these tumours are radioresistant because they are so highly differentiated and that irradiation merely diminishes the vascularity of the tumour without affecting the typical cells. The following case is cited to corroborate my conviction that irradiation is of definite value.
Case 1 A 40-year-old, obese, hypertensive woman was advised after intensive medical, otological and neurological investigation, including tomography and angiography, that the lesion involving the middle ear, jugular foramen and undersurface of the temporal bone was inoperable. She was given irradiation by 5800 rad high voltage therapy. Several months later the patient developed a facial paralysis. Repeat X-rays indicated extension of the destructive process. I felt that the prognosis was hopeless and perhaps it was justifiable to explore this patient on the outside chance that the lesion might be resectable. Mastoidectomy and a translabyrinthine approach to the internal auditory meatus were carried out and seemingly most of the tumour was removed. Three months later, however, the patient died and an autopsy was carried out. I obtained slides of the tissue removed from the undersurface of the temporal bone, which had been irradiated 6 months earlier, providing data on the effect of irradiation on all components of the tumour. The biopsy from the lesion in the middle ear revealed a rather typical glomus (Fig 1) . In the tissue removed at the time of the exploratory operation, performed 6 months after the patient had completed a full course of irradiation, a potent effect was apparent on the tumour tissue reached by radiation. The findings noted are consistent with radiation effects (Fig 2) . The many clinical instances of apparent irradiation failure may be because the radiation did not reach all the extensions of the tumour.
In another case, over 30 years ago, I removed a large tumour from the middle ear and mastoid. I left a mass of tumour tissue which was adherent to the jugular bulb, extended underneath the facial nerve in the posterior bony canal wall and presented in the mastoid cavity. The patient was given a course of 200 kV irradiation. Today, 32 years later, the patient is well, with no evidence of persistent or recurrent tumour.
My total clinical experience has strengthened my conviction that surgery, if possible, is the treatment of choice for glomus jugulare tumours. When the patient is seen late in the course of the disease and has evident extension into the pyramid or to the undersurface of the temporal bone, irradiation is recommended. I have treated recurrence after operation either by revision operation or by irradiation. In cases treated primarily by complete irradiation, surgery poses serious problems, especially as regards healing.
Deaths
There have been 7 deaths among the 47 patients who have been followed up for 5-32 years from a total of 60 cases between 1942 and 1973.
One patient died five hours after surgery of uncontrollable cerebral hypotension. One died in six months of rapid cerebral extension with metastases to the spine and chest. A third patient died of cerebral involvement eight years after the onset of the disease; she also had a squamous cell carcinoma of the breast.
Three patients had multiple neoplasms in addition to their glomus tumours: one, whose primary lesion was in the nose, was treated by surgery and irradiation, and had metastases to the spine and ribs; she lived for 14 years and died of unrelated causes. Another, treated with irradiation, died 11 years after the onset of her disease. The third died of a cerebral hemorrhage.
The seventh patient died twenty-five years after the discovery of her disease. Post-mortem examination revealed widespread involvement in the ear, lung, retroperitoneal space and spine. Originally she had an inoperable lesion in the ear and neck. Of the 7 deaths, 6 were in women and 3 had metastatic foci.
Only early recognition of this lesion will substantially reduce the mortality and morbidity. Complete post-mortem studies of patients who die should be diligently carried out to add to our knowledge of this interesting tumour and its behaviour. I have examined slides from patients who died of proven glomus tumours in the middle ear, whose so-called metastatic lesions in the lung, peritoneum, liver and spleen proved to be undifferentiated carcinomata, not glomus jugulare tumour. I had a similar experience recently when consulted about a patient with a 'glomus tumour' who was doing poorly and had severe pain. Despite all measures, the pain was not controllable. Shortly thereafter evidence of mediastinal adenopathy led to biopsy of this area. The lesion proved to be an undifferentiated carcinoma. Re-examination of the ear biopsy and needle biopsy of the prostate convinced us that we were not dealing with a glomus jugulare tumour but with a primary adenocarcinoma of the prostate, with metastasis to the middle ear and temporal bone. 6 In retrospect, it can be said that much has been learned, but more needs to be known if we are to lower the morbidity and mortality caused by glomus tumours.
Glomus jugulare tumours are exceedingly rare and, in nearly thirty years , only 48 cases have been collected at the Christie Hospital and Royal Infirmary, Manchester. Because so few cases are seen each year, it takes considerable time to build up knowledge about the natural history of the tumours and also to assess the results of various methods of treatment.
The tumours are commoner in the female sex and in this group the female to male ratio was 5:1. About three-quarters of them occurred between age 40-70 years. In this particular series there was no predominance of side of origin, but in previous reports the left side has usually been the commoner. A long-term follow up has been possible in 34 patients (71 %), on average for 8i years and the longest being 27 years.
The tumours are encapsulated and usually of very slow growth, behaving almost entirely in a benign manner but at times producing quite marked destruction within the petrous temporal bone. Rosenwasser (1945) first described a 'carotid body tumour of the middle ear and mastoid' and thought it may have arisen in the 'glomus jugularis'. Guild (1953) considered that about half of the glomus jugulare tumours arise in the adventitia of the jugular bulb and about a quarter on the tympanic nerve on the promontory of the medial wall of the middle ear. In the present study many of the tumours have arisen within the middle ear, resulting in all but one of the patients presenting initially with aural symptoms. When the tumour arises in the adventitia of the jugular bulb there is equal opportunity for it to involve the adjacent lower cranial nerves as well as the middle ear, with neurological and aural symptoms developing together.
In previous publications, it has been reported that the tumours are multicentric in origin, and Alford & Guilford (1962) quoted a 3.8% coexistence of glomus jugulare and carotid body tumours. In the cases reviewed there has been no evidence of such multicentric origin. Bickerstaff & Howell (1953) suggested a clinical grouping in relation to how the patients presented (Table 1 ). This has been most helpful in classifying the varying presentations that have occurred. Aural and neurological symptoms 5 developing concurrently Neurological manifestations 1 appearing before aural symptoms Neurological involvement 6 developing years after aural symptoms (1) Aural symptoms: Of the 48 patients, 42 (88 %) presented initially with aural symptoms, the commonest being deafness and tinnitus which often occurred together. The duration of deafness varied from months to many years and in one case for 40 years. Sometimes patients noted no subjective hearing loss but complained of a feeling of fullness or blockage in the ear. The duration of tinnitus also variedone patient had complained of it for 20 years. Most commonly, patients complain of a sensation of pulsation or throbbing. Some of the patients, even with very large tumours, never experienced tinnitus.
Spontaneous facial palsy occurred in 16 (33 %.) cases and in one was the presenting symptom. The palsy was usually permanent, but in a small number of cases recovered over a long period of time.
